Secreted, matrix-degrading proteinases have been viewed as contributing to tumor metastasis. A recent study indicates that the gene for one of these enzymes, the matrix metalloproteinase stromelysin-1, can actually cause cancer when expressed in transgenic mice. Address Tumors generally progress through a series of defined steps. A normal cell can become aberrant in the pathways that regulate its growth and death, resulting in a benign, well-circumscribed tumor. Conversion to malignancy occurs when the cells gain the ability to invade into the surrounding tissue. Malignant cells can metastasize, establishing colonies at distant sites and threatening the life of the host. The tumorigenic process is initiated by mutations in key regulatory genes, either gain-of-function mutations that generate oncogenes or loss-of-function mutations in tumor suppressor genes. Ultimately, gene expression patterns can be altered as a consequence of these mutations, resulting in changes in cellular phenotype. For example, the process of invasion involves changes in the expression of genes encoding molecules involved in cell adhesion and migration, and in the elaboration of proteinases that degrade the matrix barriers surrounding the tumor. Interactions with the vasculature and the immune system are altered as a consequence of some of these phenotypic differences. Understanding carcinogenesis at the molecular level requires an appreciation of both the genetic and the epigenetic events that contribute to tumor progression.
Tumors generally progress through a series of defined steps. A normal cell can become aberrant in the pathways that regulate its growth and death, resulting in a benign, well-circumscribed tumor. Conversion to malignancy occurs when the cells gain the ability to invade into the surrounding tissue. Malignant cells can metastasize, establishing colonies at distant sites and threatening the life of the host. The tumorigenic process is initiated by mutations in key regulatory genes, either gain-of-function mutations that generate oncogenes or loss-of-function mutations in tumor suppressor genes. Ultimately, gene expression patterns can be altered as a consequence of these mutations, resulting in changes in cellular phenotype. For example, the process of invasion involves changes in the expression of genes encoding molecules involved in cell adhesion and migration, and in the elaboration of proteinases that degrade the matrix barriers surrounding the tumor. Interactions with the vasculature and the immune system are altered as a consequence of some of these phenotypic differences. Understanding carcinogenesis at the molecular level requires an appreciation of both the genetic and the epigenetic events that contribute to tumor progression.
The matrix metalloproteinase family of zinc-dependent, extracellular proteinases are recognized as targets of oncogenic signal transduction pathways that contribute to the malignant phenotype [1] . Several members of the matrix metalloproteinase family were initially identified as the proteins encoded by oncogene-inducible or tumorspecific transcripts, and the matrix metalloproteinase genes contain elements that are highly responsive to oncogenic transcription factors. The protein products are secreted into the extracellular environment where they degrade the proteins, glycoproteins and proteoglycans of the basement membrane and extracellular matrix that form the structural scaffold of tissues. The contribution of these enzymes to tumor invasion and metastasis has been demonstrated repeatedly by studies with both the natural tissue inhibitors of metalloproteinases (TIMPs), as well as with newer synthetic matrix metalloproteinase inhibitors [1, 2] . The involvement of matrix metalloproteinases in late stages of tumor invasion and metastasis has thus been well-established.
A recent study by Sternlicht et al. [3] has given a very different picture of the role played by a secreted proteinase in malignancy. They found that overproduction of the matrix metalloproteinase stromelysin-1 in the mammary gland of transgenic mice caused changes encompassing all stages of tumor progression, ranging from hyperplasia to malignant carcinomas. In an extensive study, involving 163 mice with a median age of 18 months from five independent transgenic lines, 64% had hyperplasia, 20% had atypical proliferative lesions (dysplasia) or carcinoma in situ, and 7.4% developed mammary carcinomas. Of the nine carcinomas that developed, three showed evidence of being highly advanced and one metastasized to the lung and kidney. These results are reminiscent of classic experiments that used a transgenic approach to certify genes found mutated in cancer as oncogenes. For example, the results of expressing the Hras, myc, int/wnt-1 and neu oncogenes under the control of a mammary-specific promoter confirmed their central role in carcinogenesis [4] . Does this mean that the genes
Figure 1
Stromelysin-1 expression in a malignant tumor. Stromelysin-1 mRNA (red color) was detected by in situ hybridization in the stroma of a malignant squamous cell carcinoma that had been induced by treatment of mouse skin with a chemical initiator followed by repeated treatment with the tumor promoter TPA [10] .
Current Biology encoding stromelysin-1, and potentially those encoding other matrix-degrading proteinases, can be oncogenes?
Before assessing if a matrix metalloproteinase can be an oncogene product, the normal expression pattern of stromelysin-1 should be considered. Stromelysin-1, like most matrix metalloproteinases, is not usually expressed by the malignant tumor cells themselves, but instead is produced by the normal connective tissue (stromal) cells surrounding the tumor as part of the 'host' response to the tumor. The common adult cancers, such as breast, colon and prostate cancer, are adenocarcinomas which arise as a result of mutations in the epithelial cells that line the ductal structures in these organs. It seems that the normal cells surrounding the tumor view these changes as a wound and attempt to heal it. Inflammatory cells appear on the scene, and the fibroblasts that reside in the connective tissue surrounding the tumor become reactive. Secreted proteinases, including stromelysin-1, are produced by these fibroblasts and inflammatory cells, presumably as part of that reaction (Figure 1 ). The stroma becomes an integral part of the tumor, and there is an increasing appreciation of the contribution these non-malignant cells make to the tumor progression process.
The finding that stromelysin-1 behaves like the product of an oncogene is surprising for several reasons. Secreted proteases have been viewed as effectors of invasion and metastasis, and as such should not play a causal role in the earliest stages of tumor progression. An effect on the initiation of tumorigenesis is even more surprising if it is caused by an enzyme that is usually produced by normal stromal cells. The data, however, are unequivocal. Sternlicht et al. [3] used several approaches to confirm their results. Mammary carcinomas were observed in mice from three different founders, and two sublines of stromelysin-1 transgenic mice showed reversal of the phenotype that correlated with silencing of transgene expression. And when the stromelysin-1 transgene was crossed onto a background in which TIMP-1 was produced under the control of the same mammary-specific promoter, there was a reduction in the number of mice with mammary hyperplasia -a surrogate endpoint of tumorigenesis -from 73% to 19%. These results indicate that stromelysin-1 proteolytic activity was required for the observed effect.
As an additional test, murine mammary epithelial cells in which stromelysin-1 was expressed under the control of a tetracycline-repressible promoter were injected into the mammary fat pad of immunocompromised mice. Tetracycline-treated mice developed relatively normal ducts and glandular-like structures. Mice in which stromelysin-1 expression was induced by withholding tetracycline from the drinking water developed small tumors in 28% of the injected sites. If stromelysin-1 expression was induced in culture for two months prior to injection, 100% of the injection sites developed tumors, irrespective of the presence or absence of tetracycline in the drinking water. This suggests that the changes initiated by stromelysin-1 expression are stable and do not require continuous exposure to the enzyme.
Although stromelysin-1 expression was targeted to epithelial cells in these studies [3] , it is likely that its expression in stromal cells would have the same result. Studies with the related stromally expressed matrix metalloproteinase, stromelysin-3, have indicated a pro-tumorigenic effect of this enzyme in mammary cancer, whether it is produced by the tumor or stromal cells. Transfected human breast cancer cells expressing stromelysin-3 were found to be more tumorigenic than controls when injected subcutaneously into immunocompromised mice [5] . Similarly, the tumorigenicity of breast cancer cells was Dispatch R777
Figure 2
Normal epithelial cells can become initiated by exposure to agents that cause mutations in critical oncogenes or tumor suppressor genes. Repeated exposure to a tumor promoter can result in the development of benign tumors, which are often initially dependent on the continued treatment with the tumor promoter but can progress to become autonomous. Further genetic changes result in the conversion to a malignant tumor, characterized by the loss of an intact basement membrane. Tumor cells can become invasive and penetrate into underlying connective tissue. This connective tissue, composed of extracellular matrix, fibroblasts (blue), inflammatory cells (red), and blood vessels (tubular structures), also becomes an integral part of the tumor (grey finger-like projections). The tumor cells can circulate through lymphatic and blood vessels, invade through the vessel walls, and acquire the ability to establish a secondary tumor at a distant site -the process known as metastasis. The matrix metalloproteinase stromelysin-1 has now been shown to act as a tumor promoter in transgenic mice: in genetically-susceptible mice, it can induce the development of tumors at all stages of tumor progression. enhanced when they were mixed with stromelysin-3-expressing fibroblasts, compared to when mixed with fibroblasts derived from stromelysin-3-null mice [6] . The important substrate for the action of these enzymes is therefore likely to be either part of the extracellular matrix or on the cell surface, accessible to secreted proteinases regardless of their site of synthesis.
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How do we explain these properties of stromelysin-1? As the authors indicate, matrix metalloproteinases are not mutagens, and must therefore act by virtue of their ability to affect cellular signaling. Considerable insights into the carcinogenic process have been gained from studies with chemical carcinogens. In the two-step model of carcinogenesis (Figure 2 ), tumors are induced by a single application of a tumor initiator -a mutagen -followed by repeated application of a tumor promoter [7] . Tumor promoters, such as the phorbol ester TPA, are not mutagenic and have as one of their characteristics the ability to induce cellular proliferation, although not all growthinducing factors have tumor promoting activity. These compounds 'fix' the mutations caused by the initiator so that they are passed on to subsequent cell generations. If the mutation is in a gene that provides a growth advantage to the cell, these cells eventually dominate the population and result in a benign tumor. The benign tumors can become autonomous, no longer requiring continual exposure to the tumor promoter. Further mutations cause the conversion of the benign tumor to malignancy. Tumor development can be enhanced by genes that act as either tumor initiators or tumor promoters, as long as the other function is present.
Stromelysin-1 appears to act as a tumor promoter in mammary carcinogenesis. This would suggest that the immortal mammary cell line used in these studies is 'initiated', and that the transgenic mice also undergo a low, spontaneous rate of initiation. Interestingly, the effects of stromelysin-1 expression depended on the genetic background. Tumors did not develop on an FVB background as they did on the CD1 genetic background (Z. Werb, personal communication). And expression of stromelysin-1 under the control of a different mammary-specific promoter did not induce tumors in DBA/C57Bl6 mice [8] , as it has been shown to do on a CD1 background (M. Henderson and L. Matrisian, unpublished observation). Susceptibility to multistage carcinogenesis protocols is also highly dependent on genetic background [9] . These results would be consistent with stromelysin-1 acting as a tumor promoter in mice that are genetically prone to events that initiate mammary carcinogenesis.
The demonstration that stromelysin-1 acts as a tumor promoter for mammary carcinogenesis [3] has increased our appreciation of the role the extracellular environment plays in cancer. The considerable advances over the past decade in the field of cancer genetics have tended to emphasise those genes whose function is critical to maintaining cellular homeostasis. Mutations in these genes can initiate cancer. But an initiated cell is not a threat to the health of the host unless it is promoted and then converted to malignancy. It is becoming increasingly clear that communication between the initiated cell and its environment contributes to this process. It might prove possible to use inhibitors of matrix metalloproteinases -which are currently in clinical trials as anti-metastasis and anti-angiogenesis agents -to disrupt interactions between the tumor and its reactive stroma at any stage of tumor progression. One of the most exciting implications of this work is the possibility that matrix metalloproteinase inhibitors might be useful in reducing or preventing malignancy in high-risk populations.
